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ABSTRACT
Public and private human stem cell banking institutions are currently hosting hundreds of thou-
sands partially characterized cell populations, including a significant number of human pluripo-
tent stem cell lines. To be considered for use in clinical applications, stem cell preparations
must undergo rigorous testing in order to ensure safety for the recipient. With development of
the methodologies for in vitro derivation, ex vivo maintenance and expansion of stem cells and
targeted differentiation of multipotent and pluripotent stem cells, many novel issues were
added to the list of safety concerns of cell and tissue preparations. These issues are related to
the potential changes that may occur in the course of in vitro propagation of stem cells and
cell-derived products, how these changes may affect the quality of the preparation; and the
potential effects on the recipient. Only a limited number of studies about the role of subtle var-
iations of individual capacity for repair of genotoxic damage in maintenance in vitro of human
stem cells are currently available. Nevertheless, the assessment of individual repair capacity may
play a crucial role in the safety of use of human stem cells, as it constitutes a major factor in
the risk of occurrence of genomic alterations that may seriously compromise the quality of the
product. This article reviews the available data about the role of individual capacity for DNA
damage repair in different human stem cell types and the potential adverse effects that may
occur with the use of cell preparations with inferior repair capacity.
Abbreviations: AMD: age-related macular degeneration; DSB: double-strand break; ERCC2: exci-
sion repair cross-complementation group 2; ESC: embryonic stem cell; GVHD: graft-versus-host
disease; HPSC: haematopoietic stem cell; iPSC: induced pluripotent stem cell; MSC: mesenchymal
stem cell; NHEJ: non-homologous end joining; XPC: xeroderma pigmentosum complementation
group C; XPD: xeroderma pigmentosum complementation group D; XRCC1: X-ray repair cross-
complementing protein 1; XRCC3: X-ray repair cross-complementing protein 3
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Individual capacity for repair of genotoxic
damage as a marker of the proliferation and
differentiation capacity of stem cells
Cell therapy has become a legitimate therapeutic tool
for haematological disease, inherited metabolic disor-
ders, autoimmune disease, some types of solid
tumours such as neuroblastoma, and, lately, for mul-
tiple sclerosis refractory to other types of treatment
[1–5]. Safety for the recipient has always been a cru-
cially important part of the criteria used to assess the
potential of cell preparations for clinical applications.
This includes not only concerns about the risk of
potential transmission of infectious agents, but also
short-term effects such as survival of transplanted cells
in the recipient, engraftment capability, capacity for
rapid restoration of lost function and acute immunity-
mediated effects such as acute graft-versus-host dis-
ease (GVHD); and long-term effects such as lifespan of
the transplanted cells, self-renewing capacity of the
stem cell niche, maintenance of production of differ-
entiated cells, risk of recurrence of the primary disease
(especially in autologous transplantations), risk of
development of secondary disease (usually, neoplasia
originating from the transplanted cells) and chronic
immunity-mediated effects (chronic GVHD and others).
With development of the methodologies for in vitro
derivation, ex vivo maintenance and expansion of cells
and targeted differentiation of multipotent and
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pluripotent stem cells, a whole host of other issues
was added to the list of safety concerns of cell and tis-
sue preparations. These issues are related to the
potential changes that may occur in the course of in
vitro propagation of stem cells and cell-derived prod-
ucts, how these changes may affect the quality of the
preparation; and the potential effects on the recipient.
The proliferation potential of stem cells is typically
higher than the potential of somatic cells (although
the magnitude may significantly vary). Nevertheless,
cultured stem cells may age and/or may be suscep-
tible to carcinogenic transformation. The former may
result in lower survival, lower engraftment rates, poor
restoration of function and/or secondary disease (e.g.
aplastic anemia originating from transplanted cells);
whereas the latter may significantly increase the risk
of secondary cancer in the recipient. Already, there
have been reports about failure to sustain hematopoi-
etic engraftment after transplantation of ex vivo
expanded haematopoietic stem cells (HPSCs), develop-
ment of secondary malignancies in patients with trans-
planted HPSCs and human pluripotent cell lines prone
to genomic instability with potentially oncogenic gen-
omic rearrangements after repeated passaging [6–9].
Detection and repair of genotoxic damage/mainten-
ance of genomic integrity is critically important for
progression through the cell cycle. For non-trans-
formed somatic cells, cells that fail to comply with the
requirements of the major genomic integrity check-
points of the cell cycle (predominantly, the G1/S
checkpoint) are forced into replicative senescence
and/or apoptosis. Stem cells are inherently vulnerable
to genotoxic damage for a variety of reasons. Among
these, prominent are the ‘relaxed’ state of the chroma-
tin and the fact that the main damage checkpoint in
G1/S may not be functioning at its full efficiency in
cells of early embryos (and, respectively, embryonic
stem cells [ESCs]) [10,11]. Therefore, cells of early
embryos and ESCs that have sustained damage may
be routed to programmed cell death but may also be
induced to differentiate, as differentiated cells typically
have a functioning G1/S checkpoint [11–13]. The pro-
pensity of embryonic cells to sustain genomic damage
is at least partly overcome by increased efficiency of
the DNA repair machinery and activation of specific
mechanisms for maintenance of genomic integrity in
embryonic cells, such as Filia-dependent activation of
Parp-1 [12,14,15]. There are, however, genetic factors
that determine the individual parameters of the effi-
ciency of DNA repair. There is some degree of inter-
individual variance in the capacity to detect and repair
DNA damage even among clinically healthy individuals
[16,17]. This variance may become significant with age
(whether normal aging of the organism or aging of
cultured cells), in conditions of increased genotoxic
stress (e.g. after genotoxic treatments) and may be
associated with adverse effects on the viability, prolif-
eration and differentiation capacity of cells and cell
products that may potentially be used for transplant-
ation purposes. Several dozens of polymorphisms in
key genes coding for products functioning in DNA
repair/maintenance of genomic integrity have already
been described (analyzed in detail in [17]). Alone or in
combination with other factors, carriership of these
polymorphisms may increase the risk of degenerative
disease and/or cancer. When one or more of these
polymorphisms are present in stem cell preparations
intended for transplantation in human patients, it is
possible that their otherwise subtle effects on the
phenotype may become significant. It may be advis-
able to include molecular analysis of the capacity to
detect and repair DNA damage in the panels for ana-
lysis of safety of cell and cell-derived preparations for
transplantation purposes.
There have been a couple of studies about the role
of efficiency of DNA repair for genomic stability in cul-
tured lymphocytes showing that carriership of variant
alleles of common polymorphisms in lymphocytes
grown in vitro was associated with increased rates of
chromosomal instability [18,19]. The amount of experi-
mental data about the role of genetic polymorphisms
of DNA repair genes in the risk of development of trans-
plant-related complications is still limited.
Role of individual repair capacity for the
outcomes of treatments based on HPSC
At present, the type of stem cells most commonly used
for transplantation purposes are HPSCs and, respect-
ively, the largest body of safety data pertains to HPSC
transplantations. Transplantations of HPSCs are often
preceded by ablation of the host haematopoiesis (mye-
loablative conditioning) and are followed by immuno-
suppressive treatments. Conditioning regimens
typically include high-dose genotoxic agents that have
severe adverse effects on tissues and organs other than
the bone marrow, especially in tissues where cells have
rapid natural turnover such as the skin and the gastro-
intestinal tract. The recovery may therefore be pro-
tracted and serious complications such as GVHD arise in
no less than 35% of the recipients [20]. Acute GVHD
results predominantly from the genotoxic damage
inflicted by the pre-transplantation conditioning and its
grade may be correlated with survival (typically, higher-
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grade acute GVHD is associated with shorter survival).
Chronic GVHD arises as a result of the attack of the
immunocompetent cells in the graft on the recipient’s
tissues and may be associated with longer survival [21].
Subtle deficiencies in the capacity to manage genotoxic
damage may be at least partly responsible for the risk
of development of acute high-grade GVHD. At present,
several markers for individual capacity for DNA repair
(rs159153 in the hOGG1 gene (coding for a glycosylase
responsible for removal of oxidized bases from DNA);
rs3135974 in the LIG3 gene (coding for ligase III that is
responsible for end joining in the late stages of repair
by more than one mechanism); rs3219463 and
rs3219476 in the MUTYH gene (coding for A/G mispair-
specific adenine DNA glycosylase); rs6844176 in the
RFC-1 gene (coding for a component of the BRCA1-asso-
ciated genome surveillance complex that scans DNA for
the presence of damage) and the rs41376448 in the
HMGB1 gene (coding for HMGB1, a master regulator of
transcription and DNA repair)) have been linked to the
risk of acute and chronic GVHD and other causes of
transplant-related mortality [22–24].
In patients with transplantations of HPSCs, there is
always a risk of recurrence of the original tumour and
for development of secondary malignancies, the risk
being slightly higher in patients that have received
autologous grafts [9]. There is already a report that
grafts carrying variant alleles of genes coding for pro-
teins of DNA repair (specifically, the rs1052559 poly-
morphism in the XPD (ERCC2) gene and rs861539 in
the XRCC3 gene) may be associated with higher risk of
development of secondary leukemia [25].
Studies carried out in mouse models show that
downregulation of the capacity for repair of double-
strand breaks (DSBs) in DNA decreased the capacity
for engraftment of HPSC [26–28]. The effect was
observed with several key proteins of double-strand
break repair (Lig4, Ku80, Exo1) and was noted to
become significant with in vitro aging of the cells in
the graft. This ‘aging effect’ is a hallmark of subtle
genetic deficiencies of DNA repair/management of
genomic integrity [17].
Role of individual repair capacity for research
and potential clinical applications involving
stem cells other than HPSC
The data about the role of individual capacity for
repair of DNA/maintenance of genomic integrity for
the outcomes of transplantations of stem cells other
than HPSCs are still sparse. Presently, mesenchymal
stem cells (MSCs) are viewed as another potential
source of stem cells for transplantation purposes.
Bone marrow MSCs may be induced to differentiate to
produce several different types of specialized cells,
including osteocytes, chondrocytes, adipocytes and
endothelial cells [29]. MSCs from Wharton’s jelly of the
umbilical cord and from placenta are believed to be
pluripotent [30]. Multipotent bone marrow MSCs have
been shown to be relatively resistant to DNA damage
inflicted by inhibition of topoisomerases [31]. Studies
using ex vivo expanded MSCs, however, showed that
the efficiency of repair of double-strand breaks in DNA
tends to decline after repeated passaging [32]. To
date, freshly isolated or expanded ex vivo autologous
MSCs from bone marrow have been used in experi-
mental therapy of human patients with stroke and spi-
nal cord injury [33]. Assessment of long-term adverse
effects was carried out for the latter study and was
reported as negative [34]. Nevertheless, the number of
in vivo studies of safety of transplantation of MSCs
does not permit reliable assessment of the potential
risks.hESCs have been (and still are) a ‘gold standard’
in studies using human pluripotent cells but increased
use of human induced pluripotent stem cells (iPSCs)
lines has been recently reported [35]. According to the
Human Pluripotent Stem Cell Registry (https://hpscreg.
eu/news/single_news?id ¼72; retrieved 2018 Apr 11),
nearly 2500 human pluripotent stem cell lines (over
700 hESC lines and about 1800 iPSC lines) are pres-
ently listed as globally available. iPSCs have been
intensely studied with regard to their potential appli-
cations for the reparative and regenerative medicine.
Their use was initially limited to research purposes
only for a variety of reasons, including ‘incomplete’
reprogramming (iPSC continue to express genes typ-
ical of the cell type that they were derived from);
‘cancer-like’ expression profile, accelerated aging, low
survival and lower efficiency of differentiation [36–38].
Recently, potential future clinical applications have
begun to emerge for iPSCs as well as ESCs, including
age-related macular degeneration (AMD), vascular dis-
ease, diabetes and Parkinson’s disease [39–42]. It was
demonstrated that human iPSCs deficient for the LIG4
gene (coding for the main ligase of repair of DSBs by
non-homologous end joining (NHEJ)) exhibited signifi-
cant decrease in reprogramming efficiency than iPSC
derived from normal human cells and rapidly accumu-
lated chromosomal abnormalities [43]. Targeted differ-
entiation of these LIG4-deficient iPSCs into
haematopoietic progenitors was impaired, resulting in
accumulation of DSBs and high rates of apoptosis.
Later, it was shown that iPSCs without apparent gen-
etic defects subjected to prolonged in vitro passaging
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accumulated DSBs and exhibited mitochondrial dys-
function, increased rates of apoptosis and decreased
differentiation efficiency [44,45]. Apparently, DNA
repair is an important factor for maintenance of stem-
ness qualities of iPSC. iPSCs derived by more recent
modified methods were reported to resemble ESCs
more than iPSCs derived by traditional methods [46].
Among the main differences were increased capacity
for repair of double-strand breaks and increased accur-
acy of NHEJ for iPSCs derived by improved method-
ology, therefore, the safety of iPSC preparations in
terms of DNA repair capacity has apparently been
improved. Nevertheless, other safety concerns might
arise. These are related to the fact that there is always
an inherent risk that iPSCs derived from the patient’s
own cells may exhibit, in the course of their establish-
ment or in vitro propagation, a propensity for genetic
instability. Since carriership of polymorphisms in genes
coding for proteins directly or indirectly responsible
for the maintenance of genomic integrity is not
uncommon, this risk may be significant when using
autologous cells. Already, there has been one sus-
pended trial of treatment of human disease with iPSCs
after discovering that the autologous iPSCs intended
to be used for treatment of AMD has sustained poten-
tially dangerous mutations [47]. Consequently, desig-
nated acts regarding the safety of stem cell
preparations have been introduced (the Act on the
Safety of Regenerative Medicine (2014) in Japan,
where the trial was conducted, and the 21st Century
Cures Act in the USA (2016). The trials were only
recently resumed after the project leader Masayo
Takahashi and the Nobel laureate for 2012 Shinya
Yamanaka declared that the cells used further in the
project will be provided by the cell bank of Kyoto
University’s Center for iPSC Cell Research and
Application (headed by Yamanaka) in order to guaran-
tee that they have been comprehensively character-
ized and tested for quality. A list of recommendations
regarding future trials using iPSCs have been made,
including specific recommendations for the assess-
ment of potential risks; the choices and decisions of
the participants free of therapeutic misconception and
individualized care for the patients participating in the
trial [48]. Nevertheless, the eye is a relatively immuno-
privileged site. Potential uses of autologous iPSCs for
derivation of differentiated cells and tissues for other
than ophthalmological purposes may be limited by
histocompatibility issues. Recently, several clinical trials
for potential uses of iPSCs in neurological disease
have been launched [49,50] but no results have been
reported yet. Assessment of the individual capacity for
DNA repair/maintenance of genomic integrity may
assist in the screening of potential patients to differen-
tiate between patients that may be eligible for trans-
plantations of autologous iPSC-derived cells and
patients that may benefit from cell preparations from
allogeneic iPSCs.
Reports about the role of the capacity for repair of
DNA damage/maintenance of genomic integrity in
ESCs are still quite rare in the specialized literature.
The intact functioning of the mechanism for repair of
DNA is of prime importance for ESCs, as their restric-
tion point of the cell cycle is weak (in human ESCs) or
virtually non-existent (in murine ESCs) [11–13]. Repair
of DSBs in ESCs is important, as with all types of stem
cells. This may be especially valid for repair by hom-
ologous recombination, as it was shown to be used as
a preferred repair pathway throughout the cell cycle,
at least in murine ESCs [51]. It has been recently dem-
onstrated that the XPC-HR23B complex (normally
responsible for the identification of genomic damage
in untranscribed regions) may play a role in the con-
trol of the ‘stemness’ state in human hESCs [52,53].
This was implemented by activation of transcription of
OCT4 and SOX2 and by regulation of demethylation
of DNA via rapid excision-synthesis-end ligation cycle
that generated methylation-free DNA regions faster
than the ‘conventional’ thymine-DNA glycosylase-
mediated base excision repair. Differentiation of ESCs
into specialized cell types may be dependent on the
efficiency of specific types of DNA repair. Specifically,
differentiation along the myogenic line in human ESCs
requires temporal stimulation of the DNA repair medi-
ated by XRCC1 (a stabilizing factor of DNA ligase
III) [54].
Only recently, it has been reported that China was
on the verge of launching the first ever clinical trial
for use of hESC-derived cell products in treatment of
Parkinson’s disease [55]. It is still too early for any
results, but nevertheless, it could be expected that the
potential safety concerns would be, at least partly,
related to genomic change occurring in the process of
cell maintenance in vitro.
Apparently, the efficiency of repair of DNA damage
is an important factor for maintenance of stem cells in
culture, for efficient reprogramming back to pluripo-
tent state and for differentiation into specific cell
types. It could be expected that subtle deficiencies of
DNA repair/maintenance of genomic integrity may
affect the survival of stem cells in culture, especially
with increased passaging. Moreover, even for the stem
cell preparations prepared in strict xeno-free condi-
tions, the contact with agents with potentially
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genotoxic effects such as DMSO (dimethyl sulphoxide)
is, at present, unavoidable. Only a limited number of
studies about the role of subtle variations of individual
repair capacity in the maintenance of stem cell lines in
vitro are currently available [56,57]. Since the applica-
tions of stem cells and stem cell-derived products con-
tinue to expand and diversify, it might be advisable to
augment the currently existing panel of markers used
for characterization of stem cells and stem cell lines
with markers for individual repair capacity in order to
improve the process of selection for lines with poten-
tial use in clinical applications.
Conclusions
Knowledge about the individual DNA repair capacity
of human stem cell lines may be valuable for the pur-
poses of research, especially in light of potential geno-
type–phenotype correlations. Use of cells and cell lines
with capacity to repair genotoxic damage that is infer-
ior to the average may be undesirable for potential
clinical applications because of higher risks of engraft-
ment failure and/or potential long-term complications.
Analysis of individual capacity for repair of genotoxic
damage/maintenance of genomic integrity may
become a tool in the assessment of the capacity for
proliferation and differentiation of human stem cell
lines with regard to their potential long-term mainten-
ance in vitro and the potential in vivo applications.
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